These are the 16 Houston startups coming out of UH's RED Labs and Rice's OwlSpark

Best in class

CALI, a wearable physical therapy device for those with vertigo, pitched at the annual event. Photo via getcalibalance.com

For the sixth year, the University of Houston and Rice University have joined forces to give their student entrepreneurs a program to thrive in. RED Labs and OwlSpark, the two universities' accelerator programs, just concluded their seventh class with a presentation from the companies.

Over the past 12 weeks, these 16 startups and their teams of entrepreneurs have worked on their company, developing it, learning how to fundraise for it, and engaging with all sorts of other valuable resources and mentors through the program.

"With an emphasis on experimentation and rapid iteration, we teach disciplined startup strategies that help (students) have an eye for reducing risks and increasing odds," says Kerri Smith, managing director of OwlSpark.

This summer's cohort was hosted out of Station Houston this year, but the two universities have worked together since year two of each of their programs.

"We're very proud of our partnership, because in most other cities, two universities like this would probably be rivals, but we're interested in camaraderie and collaboration in this cohort because they are the future generation of entrepreneurs of Houston," says Kelly McCormick, director of RED Labs. "We really think that this sets an example of how working together produces better results than working against each other."

Adren

While the invention of the EpiPen and other compact anaphylaxis solutions have saved lives, the products are still too large to be constantly available to those who need it. Adren's co-founders created a collapsible autoinjector that can be work as a wristband.

"A functioning drug is only one piece of the puzzle," says Jacob, co-founder of Adren. (He didn't state his last name.) "Medication is only effective if it is accessible to the patient."

The company plans to continue on and patent their product with hopes to enter the marketplace by the next few years.

CookLab

Anyone can find a recipe for anything with the tap of a few keys and the click of of few buttons, but once you add in dietary restrictions, things get tricky. Not to mention the fact that so many healthy recipes aren't even that good for you.

The team at CookLab wants to eliminate this unregulated and confusing corner of the internet. CookLab's first product is a web tool that can determine whether or not a recipe is healthy by the user dropping in the URL. This product is in beta right now.

Down the road, CookLab wants to create a tool for users to be able to submit a recipe they want to make, then have CookLab generate a modified version that follows any dietary needs.

INSU

In a state of emergency where electricity is out, the diabetic population is forced to gamble with their lives when it comes to keeping their insulin insulated and cool.

INSU has a solution. The startup has created a battery operated cooler that can keep insulin from spoiling for 30 days. The battery can be charged by wall outlet or even solar panel.

The company plans to market directly to consumers as well as make strategic partnerships with emergency and health organizations.

auggie

Merchandise lines at concerts are quite possibly the single-most buzzkill of any show. In the age of UberEats and order-ahead apps, auggie sees a solution.

While you're at a show, you can easily order your favorite merch items on the app and choose to have it set aside for pickup that day or even get it mailed to you. The app is live on some downloading stores.

LilySpec

The speculum OB/GYNs use on their patients hasn't changed in 150 years, and, while effective, can be uncomfortable to patients during use. But this doesn't have to be the case.

LilySpec is a speculum designed with the patient in mind. The device is silently deployed, silicon coated for comfort, and adjustable for all women.

The LilySpec team will finish its clinical product this year, and the company's medical partners here in Texas will be able to use it on patients.

Myze

How do you staff a team for an unpredictable job? Emergency rooms face this challenge every single shift. Too many staffers makes the establishment bleed money, while too few causes burnout and even sacrifices quality of care.

Myze is developing a software platform that can use artificial intelligence and predictive analytics to help ERs better staff their teams.

CALI

Those suffering from Vertigo feel like the whole world has turned upside down. CALI is a device that helps those people turn it right back around.

The wearable device allows for users to do balance exercises and claim back control of their own situation.

DASH Innovations

For those relying on a catheter, changing it out requires 150 monthly procedures on average. Each one is another opportunity for infection.

DASH Innovations has created UrinControl, a urethral valve for pediatric patients that can be installed once a month and operated with a remote to control the bladder.

Get-A-Grip

Holding onto a cup is something most everyone takes for granted. For arthritis or muscle damage patients, it's a daunting daily task.

Get-A-Grip is designed to distribute the weight of the cup along the grip and make it easier and more comfortable to hold. While originally designed with these patients in mind, the grip comes in four sizes, with the smallest being perfect for babies grabbing at bottles or small children holding cups.

Everest Security

Preparing for and preventing phishing email-originated data breaches is the new normal for companies, but it's impossible to prevent employees from accidentally opening suspicious emails without thinking.

While there are plenty software protection companies out there, Everest Security couples their software solution with education, a core component for the company.

KickedOC

There are 2 million homes supposedly dedicated for off-campus housing for students, but no one-stop shop to find them. KickedOC is attempting to be that one-stop shop and make it easier for students to find their semester homes.

With listings already up in Houston, the startup hopes to expand its platform to College Station and other Texas college towns next.

Mismo Minds

Creating a creative team can be difficult if you don't have the connections already. Mismo Minds is a platform for artists, videographers, directors, etc. to join forces with others who share their creative vision. It's a social networking tool, project management platform, and job board all rolled into one.

Sports Betz

Typically for sports betting, you have two options: Impersonal bets with large pools or friendly wagers that might not ever pay off. Sports Betz is a platform where the competitive gamblers can casually bet with friends and family — but the money is pulled up front.

CIND

Chivalry is not dead, argues CIND, a new dating app. The app allows for potential matches to introduce themselves with a gift — which range from $2 to $100. Though, the recipient doesn't just walk away with the cash. The money actually goes to the recipient's nonprofit of choice. Only after the donation is made can matches start chatting.

CIND (pronounced like "Cindy") is basically digital donation dating, and everyone wins.

PCATCopycat

The Pharmacy College Admission Test isn't easy — and preparation isn't cheap.

PCATCopycat puts the power back into the hands of students. The online course is only $200 — way cheaper and easier for future pharmacists to navigate.

Second Act

Second Act is the startup that isn't. The non-company started the program with the idea of matching retirees with short-term work at various startups with the thought being that they have a lot of experience and a lot of time on their hands. While a great idea in theory, Second Act hit some walls and the company and idea are no more. The team, however, has a bright future in Houston innovation at other startups and companies.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings